A phase II clinical trial investigating the combination of nivolumab and ipilimumab, with or without stereotactic body radiotherapy, has shown promising results in halting the progression of advanced Merkel cell carcinoma (MCC). The study offers hope for patients with this aggressive skin cancer, either as a first-line therapy or after failure of previous anti-PD-1 and anti-PD-L1 monotherapy.
The randomized, open-label trial, the results of which were published in The Lancet, included patients with advanced MCC. One participant, Vincent DiMartino, a 75-year-old musician, shared his experience of being diagnosed with MCC in 2021. Initial treatment recommendations involved surgery, chemotherapy, and radiation therapy, but DiMartino opted to participate in the clinical trial at Moffitt Cancer Center.
Treatment and Outcomes
DiMartino was assigned to the combination immunotherapy and stereotactic radiation arm of the study. The results showed that 41% of patients in this arm achieved a complete response to the treatment (Lancet 400:1008-1019, 2022). DiMartino's imaging scans continue to show no evidence of disease recurrence, and he is closely monitored every 3 months.
Impact on Quality of Life
Beyond the clinical benefits, the treatment has significantly improved DiMartino's quality of life. He has been able to continue pursuing his passion for music, joining Moffitt’s house band, The ReMissions, and teaching music to seniors. “Cancer has taught me how to adjust to a new life normal and how important it is to remain an asset to your community,” DiMartino stated.
The combination therapy offers a valuable treatment option for patients with advanced Merkel cell carcinoma, providing not only disease control but also the opportunity to maintain an active and fulfilling life.
